ABSTRACT
ABSTRACT Background: Over-the-counter use of ivermectin amongst other drugs as SARS-CoV-2 treatment has been increasingly common, despite the lack of evidence on its clinical efficacy. Objective: To evaluate the effect of ivermectin use on production of antibodies against SARS-CoV-2 in health care workers (HCW) diagnosed with COVID-19 and of Th1/Th2 cytokines by stimulated peripheral blood mononuclear cells of the same cohort (PBMCs). Methods: This cross-sectional study evaluated seroconversion and neutralizing antibodies production in HCW at Complexo Hospitalar Universitário Professor Edgard Santos (Salvador, Brazil), diagnosed with COVID-19 from May to July, 2020, as well as in vitro production of antibody against SARS-CoV-2 and Th1/Th2 cytokines. Analyses were performed between December 2020 and February 2021. Participants were stratified according to the use of ivermectin (≤ 1 dose vs. multiple doses) for treatment of COVID-19. Results: 45 HCW were included (62% women). Mean age was 39 years, and disease severity was similar across groups. Neutralizing antibodies were detected less frequently in multiple doses (70%) vs. ≤ 1 dose (97%) groups, p = 0.02). PBMCs of patients in multiple doses group also were less likely to produce antibodies against SARS-CoV-2 following in vitro stimulation with purified spike protein in comparison with patients in ≤ 1 dose group (p < 0.001). PBMC's production of Th1/Th2 cytokines levels was similar across groups. Abdominal pain (15% vs 46%, p = 0.04), diarrhea (21% vs. 55%, p = 0.05) and taste perversion (0% vs. 18%, p = 0.05) were more frequently reported by participants that used multiple doses of ivermectin. Conclusions: Although there was no evidence for differential disease severity upon ivermectin use for treatment of COVID-19 it was associated with more gastro-intestinal side-effects and impairment of anti-SARS-CoV2 antibodies production, in a dose dependent manner. This potentially impacts the effectiveness of immune response and the risk of reinfection and warrants additional studies for clarifying the mechanisms and consequences of such immunomodulatory effects.
Subject(s)
Humans , Male , Female , Adult , Ivermectin , COVID-19 , Leukocytes, Mononuclear , Cross-Sectional Studies , Health Personnel , Seroconversion , SARS-CoV-2 , Antibodies, ViralABSTRACT
Objetivo: descrever as expansões temporal e geográfica da circulação do vírus Zika (ZIKV) em países e territórios, desde seu isolamento até 2018. Métodos: revisão não sistemática da literatura do período entre 1947 e 2018, utilizando a base MEDLINE e estimativas da Organização Mundial da Saúde. Resultados: desde seu isolamento em 1947, a circulação do ZIKV expandiu-se pela África, Ásia e Pacífico, até chegar à América em 2013, causando manifestações clínicas graves; as maiores soroprevalências foram registradas na ilha de Yap (74%) e no Brasil (63%); mutações genéticas, a ausência de imunidade e a alta susceptibilidade dos vetores podem ter influenciado sua transmissibilidade e ajudam a explicar a magnitude de sua expansão. Conclusão: a expansão da circulação do ZIKV nas Américas foi a mais ampla já registrada, possivelmente resultado de características populacionais e geográficas dos locais por onde o vírus circulou.
Objetivo: Describir las expansiones temporal y geográfica de la circulación del virus Zika en países y territorios, desde su aislamiento hasta 2018. Métodos: Revisión no sistemática de la literatura del período comprendido entre 1947 y 2018 utilizando la base MEDLINE y estimaciones de la Organización Mundial de la Salud. Resultados: Desde su aislamiento en 1947 la circulación del virus Zika se expandió por África, Asia y el Pacífico hasta llegar a América en 2013, causando manifestaciones clínicas graves. Las mayores seroprevalencias se registraron en la isla Yap (74%) y en Brasil (63%). Mutaciones genéticas, ausencia de inmunidad y alta susceptibilidad de los vectores pueden haber influenciado su transmisibilidad y ayudan a explicar la magnitud de su expansión. Conclusión: La expansión de la circulación del virus Zika en las Américas fue la más amplia ya registrada, posiblemente como resultado de características poblacionales y geográficas de los lugares por donde el virus circuló.
Objective: to describe the temporal and geographical expansion of Zika virus (ZIKV) circulation in countries and territories, from the time it was first isolated until 2018. Methods: This was a non-systematic literature review covering the period from 1947 to 2018 using the MEDLINE database and World Health Organization estimates. Results: Since its isolation in 1947, ZIKV circulation spread through Africa, Asia and the Pacific before reaching the Americas in 2013, causing serious clinical manifestations; the highest seroprevalence rates were recorded in Yap (74%) and in Brazil (63%); genetic mutations, absence of immunity and high vector susceptibility may have influenced ZIKV transmissibility and help to explain the magnitude of its expansion. Conclusion: The spread of ZIKV circulation in the Americas was the most extensive recorded thus far, possibly as a result of population and geographical characteristics of the sites where the virus circulated.
Subject(s)
Humans , Seroepidemiologic Studies , Epidemics/history , Epidemics/statistics & numerical data , Zika Virus/pathogenicity , Zika Virus Infection/history , Zika Virus Infection/transmission , Zika Virus Infection/epidemiology , Asia/epidemiology , Americas/epidemiology , Global Health/trends , Prevalence , Aedes/virology , Africa/epidemiologyABSTRACT
La epidemiología de enfermedades infecciosas en eventos de concentración masiva requiere de un amplio planeamiento y control por parte de los centros de salud de cada país involucrado. El Síndrome Respiratorio de Medio Oriente causado por un coronavirus es causado por un nuevo virus identificado en Medio Oriente en el 2012. Hasta octubre del 2013 se cuentan con 138 casos confirmados por laboratorio con 60 muertes. Cada año, alrededor de dos millones de peregrinos se dirigen hacia La Meca en Arabia Saudita durante el Hajj, una de las concentraciones religiosas masivas más importantes del mundo. Este año se presenta una alerta particular por el Hajj dado que el coronavirus podría ser potencialmente diseminado hacia otros países debido a la movilización de personas que implica este acontecimiento. América posee 4,6 millones de residentes musulmanes, por lo que un adecuado seguimiento de las personas que viajaron a Medio Oriente es imperativo para evitar la diseminación de este coronavirus hacia el continente. La siguiente revisión tiene como objetivo actualizar al lector sobre el tema, brindando información general de los coronavirus, especialmente sobre el que causa el Síndrome Respiratorio de Medio Oriente, la historia en el surgimiento de la enfermedad y sus manifestaciones clínicas; se propone además una serie de recomendaciones generales para las autoridades de salud de cada país para evitar así una epidemia. (MÉD.UIS. 2013;27(1):25-33).
Infectious diseases epidemiology during a mass gathering requires ample planning and implementation of control measures by health authorities in each country involved. Middle East Respiratory Syndrome caused by a coronavirus is caused by a newly identified virus in the Middle East during 2012. Until October 2013, 138 laboratory confirmed cases with 60 deaths have been reported. Every year, almost two million pilgrims direct themselves towards the Mecca in Saudi Arabia during the Hajj, one of the most important religious massive gatherings worldwide. This year represents a particular alert for this event due to the possibility that Middle East Respiratory Syndrome caused by a coronavirus can thus be disseminated throughout the world because of pilgrims' mobilization. The American continent possesses 4.6 million Muslim residents that may participate in this event. Therefore, an adequate surveillance of the people who traveled to the Middle East is mandatory in order to avoid virus dissemination to our continent. Here we present an up-to-date topic revision, giving general information about coronaviruses, emphasizing on the coronavirus causing the Middle East Respiratory Syndrome, the history of its emerging and its clinical manifestations. We propose also a series of general recommendations directed to the health authorities of each country for appropriate control of disease to prevent dissemination and a potential epidemic. (MÉD.UIS. 2013;27(1):25-33).